Our mission is to create a new category of therapeutics that repair the damage caused by devastating diseases.  Our core innovation is the discovery of a global master regulator, the Innate Repair Receptors (IRR), that produces cellular and tissue repair in various disease states. Our lead compound in clinical development, Cibinetide, is focused on addressing unmet needs in neuroscience and diabetes complications. We have developed an extensive peptide library of IRR activators, with in-vivo proof of concept efficacy for 10 unique compounds and an extensive catalogue of scientific literature in collaboration with leading academic researchers around the globe.